Overview

Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir

Status:
Recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

This is a phase III, multicenter, open-label, single-arm study of 190 virologically suppressed HIV-infected adults

Phase:

Phase 3

Details

Lead Sponsor:

The HIV Netherlands Australia Thailand Research Collaboration

Collaborators:

Department of Pharmaceutical care, Faculty of Pharmacy, Chiang Mai University
Faculty of Medical Sciences, Radboud University of Medical Center
Police General Hospital

Treatments:

Dolutegravir
HIV Protease Inhibitors
Protease Inhibitors
Ritonavir
Tenofovir